Demant (DEMANTN) Q2 2026 Earnings Report

The call presented a largely positive operational and financial picture: strong top-line growth (15% reported), margin expansion, robust cash generation, deleveraging progress, a successful product (Zeal) and a new flagship (Reveal) with promising technology. Challenges include elevated special items and integration costs, FX headwinds, weakness in China, managed-care softness in the U.S., and uncertainty around competitive launches. On balance, the positive growth, margin improvement and upgraded guidance outweigh the headwinds.

Demant upgraded its 2026 guidance to organic revenue growth of 6–7% and EBIT before special items of DKK 4.4–4.8 billion, with special items now expected to total DKK 400 million (KIND integration DKK 150m, cost‑saving initiatives DKK 250m); management also expects the cost‑effectiveness program to deliver DKK 300m (vs DKK 250m prior), KIND to contribute about DKK 325m to EBIT (vs DKK 300m) and a tariff refund of DKK 25m in H2. This outlook assumes a full‑year hearing‑aid market of roughly 3–4% (H1 was ~4% value / 3% units, Q2 ASP +1%), and follows H1 reported group growth of 15% (organic 7%, acquisitive 10%, FX -3%), gross profit up 17% to just shy of DKK 10bn with gross margin +1.1pp, EBIT before special items of DKK 2.134bn (16.5% margin), OpEx organic +5% (acquisitions +14% to OpEx), operating cash flow of DKK 1.6bn (+6% y/y), and net leverage at 3.0 with an expectation to be slightly above the 2.0–2.5 target range by year‑end.